Teva Pharmaceutical Industries (NYSE:TEVA) Releases Q1 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its first quarter 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.520-0.520 for the period, compared to the consensus estimate of 0.480. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion. Teva Pharmaceutical Industries also updated its FY 2025 guidance to 2.350-2.650 EPS.

Teva Pharmaceutical Industries Trading Down 1.2 %

TEVA opened at $15.50 on Friday. The firm has a market capitalization of $17.57 billion, a P/E ratio of -10.68, a P/E/G ratio of 1.44 and a beta of 0.82. The firm’s 50 day moving average is $17.35 and its 200-day moving average is $18.14. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 52-week low of $12.51 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on TEVA. Bank of America reduced their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.